{ "schema_version": "uw.editorial_geo.v1", "representation_profile": "lossless_source_sections", "local_stage_only": true, "catalog_id": "DEP-05-N05", "article_index": "DEP-05-N05", "language": "en", "headline": "Sedatives and GHB", "description": "Sedatives and GHB", "short_answer": "*Distinguishing relief, dangerous suppression of consciousness, and withdrawal risk — without experiments at home*\n\nA person may genuinely feel better: anxiety recedes, rest becomes possible, and something that once felt unmanageable becomes manageable. That experience need not be dismissed to discuss addiction. Yet relief, safety, physical adaptation, and a substance use disorder answer different questions. These distinctions matter especially when a substance can suppress consciousness and breathing, while stopping it after physical dependence has developed can also be dangerous.\n\nThis article helps prepare a request for help. It does not determine your diagnosis or offer a method of use or withdrawal on your own. In immediate danger, local emergency medical help takes priority over preparing a conversation.", "short_answer_source": { "kind": "opening_after_h1", "role": "lead", "start_utf16": 21, "end_utf16": 842, "sha256_utf8": "5358ea5a7d26d2e04a2d7ef1dfaf4083c43735359759b7ae3607232d4b025ed7" }, "headline_source": { "role": "h1_heading", "start_utf16": 2, "end_utf16": 19, "sha256_utf8": "8f86cc99549d55c68a7cdb37bb815d8ad854641c62eba5c06cf2e42baa421550" }, "entities": [], "questions": [ { "q": "One broad term, different substances", "a": "“Sedatives” is a broad description of substances with calming or depressant effects, not the name of a single, uniform medicine. Benzodiazepines and GHB, for example, cannot be treated as interchangeable substances with one shared pattern of risk. The FDA discusses medical benefits and risks specifically for the benzodiazepine class; those findings cannot automatically be extended to everything that causes drowsiness. [FDA benzodiazepine warning](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class).\n\nGHB is gamma-hydroxybutyric acid, also known by the Russian abbreviation GOMK. Related substances GBL and 1,4-butanediol can be converted to GHB in the body. The UK's 2020 ACMD review considers them together in many discussions of harm, while noting limitations in the separate evidence on precursors. This does not make them identical in every medical or legal respect. [ACMD review](https://assets.publishing.service.gov.uk/media/5fb6af25d3bf7f63e41e5e59/Final_GHBRS_report_20_November_2020.pdf).\n\nThe medicinal form has a separate context. The US Xyrem label, hosted by DailyMed and revised in July 2025, specifies indications in narcolepsy: cataplexy or excessive daytime sleepiness. Its active ingredient is sodium oxybate, the sodium salt of GHB. Such prescribing requires medical oversight; it does not authorize extending medicinal use to nonmedical use. The US label also does not establish availability or identical legal status in Russia, Thailand, or other countries. [Xyrem label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca).", "source_spans": [ { "role": "h2_heading", "start_utf16": 847, "end_utf16": 883, "sha256_utf8": "42eeace741470fa1000759de497ac28e9150f3e6fd5b89b19d950ba71756a127" }, { "role": "h2_answer", "start_utf16": 885, "end_utf16": 2562, "sha256_utf8": "a549697da1818107867ee71b0d17ee280cb62ea6769b7c9c47be05401cb1b922" } ], "block_ids": [ "p0006", "p0007", "p0008" ], "source_segment_index": 1 }, { "q": "Benefit, adaptation, and loss of control", "a": "A benzodiazepine can be helpful when appropriately prescribed. Physical dependence and dangerous withdrawal can nevertheless occur during prescribed use. A prescription alone does not eliminate risk, and physical adaptation alone does not establish a substance use disorder. The FDA maintains both points: medical benefit and the need for individual assessment. [FDA](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class).\n\nIt helps to distinguish several questions in a conversation: does treatment relieve a particular complaint; how is the person's condition changing; can the agreed plan be followed; and what is happening to control, responsibilities, and consequences? Nonmedical use also does not allow someone to diagnose a person from a single episode. The Xyrem label distinguishes nonmedical use, use contrary to prescribing instructions, and addiction; they do not necessarily coincide. This distinction is not a diagnostic test to use at home. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca).\n\nContinued work, pleasure, or a subjective sense of clarity deserves attention. None measures breathing or guarantees safety. Assessment should not rest on dividing people into “strong” and “weak” minds, or on assuming that all relief is imaginary.", "source_spans": [ { "role": "h2_heading", "start_utf16": 2567, "end_utf16": 2607, "sha256_utf8": "44fbc202cac7d10cdcda7ae80483712041c4119baa002fbfac68f04edc2f9e3b" }, { "role": "h2_answer", "start_utf16": 2609, "end_utf16": 4002, "sha256_utf8": "fa25ad3421002849a53a84e8c652abcefe4d10de2ce3b844a12741574fa8d04c" } ], "block_ids": [ "p0010", "p0011", "p0012" ], "source_segment_index": 2 }, { "q": "When help is needed now", "a": "If a person is hard to wake, unresponsive, breathing poorly, or having a seizure, seek local emergency medical help immediately. Do not wait for every sign, the exact substance name, a test result, or an admission of use. Suspected poisoning requires urgent medical advice even when its cause and severity are still unclear. [NHS: poisoning](https://www.nhs.uk/conditions/poisoning/).\n\nGHB and related substances can profoundly suppress consciousness and breathing. The ACMD review identifies combination with alcohol and other depressants, including benzodiazepines, as an additional risk factor. [ACMD](https://assets.publishing.service.gov.uk/media/5fb6af25d3bf7f63e41e5e59/Final_GHBRS_report_20_November_2020.pdf). The medicinal form also carries serious warnings: the Xyrem label describes respiratory depression and increased danger from interactions with other central nervous system depressants, including opioid pain medicines. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca).\n\nLoss of consciousness cannot be explained away as a person's habit of “just sleeping like that.” A relative need not establish the chemical cause before calling for help. Tell professionals what is already known; do not delay seeking help to search for packaging, messages, or a reconstruction of events. An immediate threat of suicide or self-harm also requires local emergency help. [NIMH: depression and immediate danger](https://www.nimh.nih.gov/health/publications/depression).", "source_spans": [ { "role": "h2_heading", "start_utf16": 4007, "end_utf16": 4030, "sha256_utf8": "d04e94a03fad5f72040f2ef2a11b672f7c4e179ce8dd57e76045a6c12558dc5e" }, { "role": "h2_answer", "start_utf16": 4032, "end_utf16": 5559, "sha256_utf8": "bf67cd099480e999d543e57e393008c450f7bf24f2427acfbe224502b5524ad7" } ], "block_ids": [ "p0014", "p0015", "p0016" ], "source_segment_index": 3 }, { "q": "Withdrawal is a different danger", "a": "Acute suppression of consciousness and withdrawal are different conditions. In a person physically dependent on GHB or related substances, withdrawal can involve severe confusion, hallucinations, seizures, and become life-threatening. The ACMD emphasizes this danger while describing limitations in research on clinical treatment. Reading the review does not provide an individual withdrawal plan. [ACMD](https://assets.publishing.service.gov.uk/media/5fb6af25d3bf7f63e41e5e59/Final_GHBRS_report_20_November_2020.pdf).\n\nThe danger of abruptly stopping benzodiazepines also requires discussion with a professional. Do not take a break to test willpower or “prove there is no dependence”; do not change prescribed treatment on your own in pursuit of purity. [FDA](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class). This is not an instruction to continue nonmedical use until a convenient date: the task is to obtain a medical assessment of how changes can be made safely. Severe confusion, hallucinations, seizures, or immediate danger require emergency help, rather than waiting for a routine appointment.\n\nThere is no common timetable of safe withdrawal for every sedative and every person. A friend's account of “getting through it” does not determine your risk. The choice of help depends on the particular substance, the medical prescription, the person's condition, and circumstances already known.", "source_spans": [ { "role": "h2_heading", "start_utf16": 5564, "end_utf16": 5596, "sha256_utf8": "d071a7d9eb0e11ffb5275a4caec3043de4c249c9a7392e2535da68b44ab837b3" }, { "role": "h2_answer", "start_utf16": 5598, "end_utf16": 7085, "sha256_utf8": "f8747e115d15f427ab78cc437d32f536c9e3b20d83e8db54f72d9ddc58e03a01" } ], "block_ids": [ "p0018", "p0019", "p0020" ], "source_segment_index": 4 }, { "q": "One substance does not explain everything", "a": "Anxiety, insomnia, low mood, and difficulties in life can precede use, accompany it, or have several causes. The order of events alone does not establish a cause. Overlapping complaints call for joint assessment of mental health, medication treatment, and substance use; NIMH emphasizes integrated care when mental disorders and substance problems co-occur. [NIMH: co-occurring conditions](https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health).\n\nFor a first contact, you do not have to settle in advance what is happening, find hidden trauma, or persuade relatives to accept one account of your history. You can say directly: “This helps me, but I am afraid of losing control and of unsafe withdrawal.” That statement keeps both the benefit and the question of risk in view. Help should not wait for perfect sobriety, an exhaustive explanation, or the family's complete agreement.", "source_spans": [ { "role": "h2_heading", "start_utf16": 7090, "end_utf16": 7131, "sha256_utf8": "b4c51bc55f46ff9cb628b3f1b1a1354969d2cad6e5e5835f51879552a2057dc8" }, { "role": "h2_answer", "start_utf16": 7133, "end_utf16": 8031, "sha256_utf8": "a17aaf97526abf5d79ac77952df9762985ab39ada86f812c49d78aa596df30e8" } ], "block_ids": [ "p0022", "p0023" ], "source_segment_index": 5 }, { "q": "First contact without promising easy access", "a": "When there is no emergency, you can contact the prescribing clinician, a medical service that deals with substance use problems, or start with an accessible medical professional. Ask whether the service can assess sedatives or GHB specifically and the safety of changing use. An appointment with any counselor should not be treated as a substitute for medical assessment of withdrawal risk.\n\nYou can ask about the earliest opportunity for contact, cost, communication language, and what to do if the service cannot provide the help needed. These questions matter particularly when shame, financial constraints, transport problems, or the absence of a nearby specialist make access difficult. Preparing questions and checking appointment arrangements may help organize contact; they do not guarantee a place, payment, or a treatment outcome. [SAMHSA: arranging a first appointment](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment).\n\nIf the first service declines or does not deal with such conditions, that does not establish that help is impossible. Ask about an available referral or another medical route. An agreed date means an arrangement to make contact, not treatment already received, and not a deadline by which the person must stop using on their own.", "source_spans": [ { "role": "h2_heading", "start_utf16": 8036, "end_utf16": 8079, "sha256_utf8": "b02a772abe0f3bb3e178a52f1445fb456543453d5f3b473e28be8611ff8a5517" }, { "role": "h2_answer", "start_utf16": 8081, "end_utf16": 9382, "sha256_utf8": "1ac25f1923ff1cbb7cf34d4cd274e182e134ba7a0c71efc08941c39ca78ae507" } ], "block_ids": [ "p0025", "p0026", "p0027" ], "source_segment_index": 6 }, { "q": "For relatives: involvement with boundaries", "a": "Manageable support can be concrete: find a service together, help with translation or transport, or attend a conversation if the person wants you there. A relative has the right to state which consequences are unacceptable to them. Caring for yourself and drawing on other sources of support matter too; a relative need not become the only rescuer. [SAMHSA: caring for yourself while helping someone](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself).\n\nDiscuss harm already observed, without turning uncertainty or disagreement into evidence of a diagnosis. Do not demand a public confession, arrange tests through use or withdrawal, or ask a child to monitor an adult. The limits of an adult relative's involvement and the person's consent should be discussed separately from a medical emergency.\n\nWhere there is violence or threats, priority goes to protecting the person harmed and children, accessible local help, and safe distance. Love does not require remaining close to danger, forgiving harm, or promising that the right conversation will make someone accept treatment.", "source_spans": [ { "role": "h2_heading", "start_utf16": 9387, "end_utf16": 9429, "sha256_utf8": "d52ec021fa8c31bcd7bee8c0efb5031ff63b521dd1b32cfd1075fbbcc266be17" }, { "role": "h2_answer", "start_utf16": 9431, "end_utf16": 10532, "sha256_utf8": "8ba3195c7c98390c2d934abd8efbd2a81094c47bceb502dbfa454bd496e131dc" } ], "block_ids": [ "p0029", "p0030", "p0031" ], "source_segment_index": 7 }, { "q": "Five optional notes for seeking help", "a": "If there is no emergency now, you can briefly record what is already known. Nothing needs to be checked through new use, withdrawal, or questioning against a person's wishes. Not knowing is acceptable too: “I am not sure” is more accurate than an invented answer.\n\n1. **What is known about the substance or prescription?** A name from an existing prescription or package, if known. If the name is uncertain, say so; do not try to identify the substance by trying it.\n2. **What was the genuine benefit?** Which complaint eased, or which task became more manageable? Keep this in the conversation about further help.\n3. **What is already concerning?** Known instances of loss of control, suppressed consciousness, adverse consequences, or worsening during a previous change in use. Do not provoke another episode to create a record.\n4. **What else should the professional know?** Medicines, other substances, complaints, and safety circumstances already known. Incomplete information should not delay urgent help.\n5. **What contact is accessible, and what support is needed to reach it?** A service or professional, appointment questions, language, transport, and a relative's voluntary involvement. If no suitable contact is known yet, finding one can be the first action; the contact date is not a deadline for withdrawal on your own.\n\nThis is original preparation for a conversation, not a validated test, a detoxification plan, or treatment. You can seek help with one item completed or with no notes at all. Relief, safety, and regaining control deserve to be discussed together: respecting a person does not require silence about risk, and acknowledging risk does not require dismissing everything that has helped them.", "source_spans": [ { "role": "h2_heading", "start_utf16": 10537, "end_utf16": 10573, "sha256_utf8": "a936a119b3bd2c3761e88b0c7a9b466bc5e8fedd0df4f05b2e4957874740e511" }, { "role": "h2_answer", "start_utf16": 10575, "end_utf16": 12298, "sha256_utf8": "bc669ee1cccec58310c94302744416f99055aeabcbef9e65c0d14ba24e701107" } ], "block_ids": [ "p0033", "p0034", "p0035" ], "source_segment_index": 8 }, { "q": "Sources and limits", "a": "Prepared on 14 October 2026. ACMD is a UK review from 2020, not today's legislation or a reading of every included study. DailyMed hosts a specific US Xyrem label revised 07/2025; its clinical and regulatory context is not universal. Medical pages do not determine an individual reader's condition. Access arrangements depend on the country and service. The practical questions above are original and have no established independent therapeutic effect.\n\n- [ACMD. Assessment of harms of GHB, GBL and related compounds, 2020](https://assets.publishing.service.gov.uk/media/5fb6af25d3bf7f63e41e5e59/Final_GHBRS_report_20_November_2020.pdf).\n- [DailyMed. Xyrem label, revised 07/2025](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca).\n- [FDA. Benzodiazepine class warning, 23 September 2020](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class).\n- [NHS. Poisoning, reviewed 12 June 2025](https://www.nhs.uk/conditions/poisoning/).\n- [NIMH. Substance use and mental health, reviewed March 2025](https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health).\n- [NIMH. Depression, revised 2024](https://www.nimh.nih.gov/health/publications/depression).\n- [SAMHSA. How to set up an appointment, 24 April 2023](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment).\n- [SAMHSA. Taking care of yourself, 24 April 2023](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself).", "source_spans": [ { "role": "h2_heading", "start_utf16": 12303, "end_utf16": 12321, "sha256_utf8": "f91f16500d95114ea5dd62762b302ab95f247ca4f49fe0affb04993b09f0a299" }, { "role": "h2_answer", "start_utf16": 12323, "end_utf16": 13877, "sha256_utf8": "ac7624f04770fdd8d51901798a56a58722bb478fcecfe00db1b1c6398fdc546e" } ], "block_ids": [ "p0037", "p0038" ], "source_segment_index": 9 }, { "q": "Topics", "a": "Sedatives; GHB and GOMK; GBL and precursors; medicinal oxybate; benzodiazepines; physical dependence; substance use disorder; respiratory depression; dangerous withdrawal; seeking help; relatives' involvement; personal boundaries.", "source_spans": [ { "role": "h2_heading", "start_utf16": 13882, "end_utf16": 13888, "sha256_utf8": "e22820fcf5cd90e3fdd99a7569e0ee2f30eb7ebadfb2fe4d159b30c166ff81b7" }, { "role": "h2_answer", "start_utf16": 13890, "end_utf16": 14120, "sha256_utf8": "43b5400010cf5d7f834ebd2229a46dc2a3af4278e21ab0d3a430f4ad8f1bd7da" } ], "block_ids": [ "p0040" ], "source_segment_index": 10 }, { "q": "About the authors", "a": "Andrey Zarinsh is the author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue, and contemporary spiritual discipline. Instagram: @andrey.zarinsh.\n\nMaria Evilkut is a co-author of United Wisdom. Alongside research, she seeks to test these ideas in practice and observe how principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.\n\n*United Wisdom · DEP-05-N05 · English version · 14 October 2026*", "source_spans": [ { "role": "h2_heading", "start_utf16": 14125, "end_utf16": 14142, "sha256_utf8": "e120452a2b9952200310f55df00e52d0bbd068d32bba8a322511ed65e3d4967d" }, { "role": "h2_answer", "start_utf16": 14144, "end_utf16": 14657, "sha256_utf8": "6a17d29e1df0105397db30407aa108c56ac2739e0c422ade9e00058853865714" } ], "block_ids": [ "p0042", "p0043", "p0044" ], "source_segment_index": 11 } ], "claims": [], "claims_policy": "no_reclassified_claims", "sources": [ { "id": "src_463998ce56ffef4c", "title": "FDA. Benzodiazepine class warning, 23 September 2020", "url": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class", "source_spans": [ { "role": "markdown_link", "start_utf16": 1307, "end_utf16": 1470, "sha256_utf8": "b27b90f22f552ba25e46f2de157497d52bfccd839795da1a5a2533d2e83df1f5" }, { "role": "markdown_link", "start_utf16": 2971, "end_utf16": 3111, "sha256_utf8": "8d88587e2efbfe2f764ff280b0c1eb3fafb643ea157568fc047a2e6477ace212" }, { "role": "markdown_link", "start_utf16": 6354, "end_utf16": 6494, "sha256_utf8": "8d88587e2efbfe2f764ff280b0c1eb3fafb643ea157568fc047a2e6477ace212" }, { "role": "markdown_link", "start_utf16": 13102, "end_utf16": 13291, "sha256_utf8": "eb447fe838eed3f8fa3882a139fd75f64f3cbb003ffb1df9dd40310b94034f54" } ], "read_scope": "- [FDA. Benzodiazepine class warning, 23 September 2020](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class).", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13100, "end_utf16": 13292, "sha256_utf8": "e1804fdba92358f5dcc7f5549d6f778dec56c183ed9bcedfc5056f619e4f625b" }, "shared_entry_urls": [] }, { "id": "src_d307f023b9560330", "title": "ACMD. Assessment of harms of GHB, GBL and related compounds, 2020", "url": "https://assets.publishing.service.gov.uk/media/5fb6af25d3bf7f63e41e5e59/Final_GHBRS_report_20_November_2020.pdf", "source_spans": [ { "role": "markdown_link", "start_utf16": 1844, "end_utf16": 1970, "sha256_utf8": "8fadd134d3f85b6c826db1f38fbd8de66ffcec312848669fa1e715b88302d1d3" }, { "role": "markdown_link", "start_utf16": 4630, "end_utf16": 4749, "sha256_utf8": "b3356188adb2a837c7e030df1c3978b16add73c75e1e64edc90104405c8978da" }, { "role": "markdown_link", "start_utf16": 5996, "end_utf16": 6115, "sha256_utf8": "b3356188adb2a837c7e030df1c3978b16add73c75e1e64edc90104405c8978da" }, { "role": "markdown_link", "start_utf16": 12779, "end_utf16": 12959, "sha256_utf8": "e155b99f37ebc15c9893e66503863acae32fa36c852a02e353ef636da4a2f61f" } ], "read_scope": "- [ACMD. Assessment of harms of GHB, GBL and related compounds, 2020](https://assets.publishing.service.gov.uk/media/5fb6af25d3bf7f63e41e5e59/Final_GHBRS_report_20_November_2020.pdf).", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12777, "end_utf16": 12960, "sha256_utf8": "70479581613e6390d067cdaca822353de49e052fca74d8a6b01444f07b154fad" }, "shared_entry_urls": [] }, { "id": "src_3fa760b2f2a5e168", "title": "DailyMed. Xyrem label, revised 07/2025", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca", "source_spans": [ { "role": "markdown_link", "start_utf16": 2453, "end_utf16": 2561, "sha256_utf8": "5f0924dc8712d85fb4c93a112cbaee98b9dcd78e80778bb21a39fcc7b943d2f2" }, { "role": "markdown_link", "start_utf16": 3647, "end_utf16": 3752, "sha256_utf8": "c66bdc913e33d8b84fe268275c7fbfe2bfaa160fd55cf3fcb0e5b696be822092" }, { "role": "markdown_link", "start_utf16": 4969, "end_utf16": 5074, "sha256_utf8": "c66bdc913e33d8b84fe268275c7fbfe2bfaa160fd55cf3fcb0e5b696be822092" }, { "role": "markdown_link", "start_utf16": 12963, "end_utf16": 13098, "sha256_utf8": "1baedcc2782a25fa6922a8e6b30f7deccdafdc1eac23b0e34c1ca27e82762d82" } ], "read_scope": "- [DailyMed. Xyrem label, revised 07/2025](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926eb076-a4a8-45e4-91ef-411f0aa4f3ca).", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12961, "end_utf16": 13099, "sha256_utf8": "c97f95af78473a19e3312bd79421acc4e141f7e50a3bd4d391843b743383ab9d" }, "shared_entry_urls": [] }, { "id": "src_10790fb1fab48f9a", "title": "NHS. Poisoning, reviewed 12 June 2025", "url": "https://www.nhs.uk/conditions/poisoning/", "source_spans": [ { "role": "markdown_link", "start_utf16": 4357, "end_utf16": 4415, "sha256_utf8": "4d85af2a7956996aa04bd18e26aa19fa39877d98a0b764fbba72d74397509d87" }, { "role": "markdown_link", "start_utf16": 13295, "end_utf16": 13376, "sha256_utf8": "7d4112ba76f9352d2ac9800019e333de6fdc3039d5efeaef1cd315a71a25e118" } ], "read_scope": "- [NHS. Poisoning, reviewed 12 June 2025](https://www.nhs.uk/conditions/poisoning/).", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13293, "end_utf16": 13377, "sha256_utf8": "002cb8a9a6c87cca39a585694fcd2b8c2b0d13bec3d8f2a52099b968a5b215e9" }, "shared_entry_urls": [] }, { "id": "src_a16ec569ffdc8d21", "title": "NIMH. Depression, revised 2024", "url": "https://www.nimh.nih.gov/health/publications/depression", "source_spans": [ { "role": "markdown_link", "start_utf16": 5462, "end_utf16": 5558, "sha256_utf8": "f9661b54ba56e6ddd0bd582087872f119cb7c9ce05b4589bb3552943b9f4b585" }, { "role": "markdown_link", "start_utf16": 13516, "end_utf16": 13605, "sha256_utf8": "b77e9e0f206e00d6074fd441c4834bf0a0d2df49dabef844f85a716b0ffd3f41" } ], "read_scope": "- [NIMH. Depression, revised 2024](https://www.nimh.nih.gov/health/publications/depression).", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13514, "end_utf16": 13606, "sha256_utf8": "fe667e89f38b74d77879e98396ea5e97fc3e0f37abac84877a9c6e864551a3ea" }, "shared_entry_urls": [] }, { "id": "src_ccd9c1d7863aff81", "title": "NIMH. Substance use and mental health, reviewed March 2025", "url": "https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health", "source_spans": [ { "role": "markdown_link", "start_utf16": 7491, "end_utf16": 7594, "sha256_utf8": "ed38e54cc2bcacdd32271c79cb68111ddfd2901408da29a885a3f881cfc2dd5c" }, { "role": "markdown_link", "start_utf16": 13380, "end_utf16": 13512, "sha256_utf8": "2d322a9cb2880a00d0063a886b59702ed42847d8e6851f829a3345db56d28e2e" } ], "read_scope": "- [NIMH. Substance use and mental health, reviewed March 2025](https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health).", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13378, "end_utf16": 13513, "sha256_utf8": "246c7a1543c9887582f67ea7afc59eb485990a3decd63521ca2591d6eace070f" }, "shared_entry_urls": [] }, { "id": "src_96d8458a638ca14b", "title": "SAMHSA. How to set up an appointment, 24 April 2023", "url": "https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment", "source_spans": [ { "role": "markdown_link", "start_utf16": 8922, "end_utf16": 9050, "sha256_utf8": "3c9fec17ea31fd9369a53b3753130379f54453c3dca8e76ddc5cfb7ecd88c637" }, { "role": "markdown_link", "start_utf16": 13609, "end_utf16": 13751, "sha256_utf8": "67cb1107cb8d5845d9f2a602c0ac31ede339251d33eda0900225e2aea175f356" } ], "read_scope": "- [SAMHSA. How to set up an appointment, 24 April 2023](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment).", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13607, "end_utf16": 13752, "sha256_utf8": "091f2bce1bb99754cc798aebd4bac475b2e78b27690d6baff3071863b8f8eeb8" }, "shared_entry_urls": [] }, { "id": "src_c7cfed956c8066f2", "title": "SAMHSA. Taking care of yourself, 24 April 2023", "url": "https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself", "source_spans": [ { "role": "markdown_link", "start_utf16": 9780, "end_utf16": 9904, "sha256_utf8": "caca72f73f1362f1d0e4ecb088e351f45ddf74b97dc438bdc56dc028fd3e42eb" }, { "role": "markdown_link", "start_utf16": 13755, "end_utf16": 13876, "sha256_utf8": "55b1832a3fbe68ed5d4e22c22b1cbff24276dd9b23c58eac52b15b08cce6c715" } ], "read_scope": "- [SAMHSA. Taking care of yourself, 24 April 2023](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself).", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13753, "end_utf16": 13877, "sha256_utf8": "e1f09757adb7a208826ce97519a44556b304478a748d2e878665fa0ad68f7a76" }, "shared_entry_urls": [] } ], "retrieval_limits": [ "This local GEO representation applies only to the specified source article version and its SHA-256.", "Qualifications, sources and attributions remain in the full sections and byte-identical Markdown copy.", "No new source research was conducted in this GEO stage." ], "master_sha256": "4ea3c963786bf34840624dc13e9dcd6709023280f37dd1dae86c1923c131c9f8", "provenance": { "raw_reader_sha256": "4ea3c963786bf34840624dc13e9dcd6709023280f37dd1dae86c1923c131c9f8", "ru_master_sha256": "6870a74f0a6a1b5d90feeb872d331eb3dd0a4525157ef93454904e9a652068bf", "reader_path": "outputs/uw-addictions-corpus-20261013/articles/DEP-05-N05/ARTICLE_EN.md", "review_pointer": "outputs/uw-addictions-corpus-20261013/articles/DEP-05-N05/INDEPENDENT_REVIEW.json", "review_sha256": "3b2a84e64409da985660ce5c35cd5b1789a073e49deab21ba0faf102839aa845", "clean_md_relative_filename": "GEO.en.md", "body_length_utf16": 14658, "source_segments": [ { "kind": "opening", "index": 0, "heading": null, "start_utf16": 0, "end_utf16": 844, "sha256_utf8_raw_slice": "5f4e7ce6c5ea3e44f53aaee75eebc65b4bbbe675f1e45de4b02a4eb0d3305eba" }, { "kind": "h2_section", "index": 1, "heading": "One broad term, different substances", "start_utf16": 844, "end_utf16": 2564, "sha256_utf8_raw_slice": "69e16d2c8f0070242aefcdd734ada841374ac3bb79525eac11c483250d6e5fdb" }, { "kind": "h2_section", "index": 2, "heading": "Benefit, adaptation, and loss of control", "start_utf16": 2564, "end_utf16": 4004, "sha256_utf8_raw_slice": "b5b4d4b6aaf8a69a435875ba8c51c70fd24e0d1baccd5698e07485cdfd375049" }, { "kind": "h2_section", "index": 3, "heading": "When help is needed now", "start_utf16": 4004, "end_utf16": 5561, "sha256_utf8_raw_slice": "f0786e03798d2b64a31186d64b7618593aa12fe336ae042e456bb0e9121abf7a" }, { "kind": "h2_section", "index": 4, "heading": "Withdrawal is a different danger", "start_utf16": 5561, "end_utf16": 7087, "sha256_utf8_raw_slice": "eb125541688ccd87e5d15c6d8839dd82adc0b31596ae3f255c28b4b954f4011d" }, { "kind": "h2_section", "index": 5, "heading": "One substance does not explain everything", "start_utf16": 7087, "end_utf16": 8033, "sha256_utf8_raw_slice": "3cad53c467200ffd033e62c26a90ff36078e46e3304f5391bebf70e2682a6711" }, { "kind": "h2_section", "index": 6, "heading": "First contact without promising easy access", "start_utf16": 8033, "end_utf16": 9384, "sha256_utf8_raw_slice": "0279c510cf766361b982fa72dedf1148e6d19e6e286edbe2ff96056d36d797c3" }, { "kind": "h2_section", "index": 7, "heading": "For relatives: involvement with boundaries", "start_utf16": 9384, "end_utf16": 10534, "sha256_utf8_raw_slice": "d345e5b77c9c7600ca7d47522ada01a9293e6935f279ce3c0cd43672a977ca84" }, { "kind": "h2_section", "index": 8, "heading": "Five optional notes for seeking help", "start_utf16": 10534, "end_utf16": 12300, "sha256_utf8_raw_slice": "237b808e827b12f8b5972801bc9178b405ef271266e2db6544fb0c792c53e20c" }, { "kind": "h2_section", "index": 9, "heading": "Sources and limits", "start_utf16": 12300, "end_utf16": 13879, "sha256_utf8_raw_slice": "bf77b5b3962d2bad7766da3406591377ef95c08713332d2e3c865995745966cd" }, { "kind": "h2_section", "index": 10, "heading": "Topics", "start_utf16": 13879, "end_utf16": 14122, "sha256_utf8_raw_slice": "8baad7f9f457404249b7c5d6296da6dfcf5d9e0cdf4a50c9c16b1032ee783f0c" }, { "kind": "h2_section", "index": 11, "heading": "About the authors", "start_utf16": 14122, "end_utf16": 14658, "sha256_utf8_raw_slice": "f9b8d3ca315f4f40bdfc52a62d60381b44b3c4471de61700e051526331dc8d16" } ], "common_blocks_module_sha256": "6cf638661a819f960c39d08058bf6d0d0696e8b816f677d95b389f5f1d11e4d2" } }